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Background: This study aimed at identifying risk factors of recurrence for completely resected pathologic T1aN0M0
lung adenocarcinomas.
Methods: We reviewed the records of 177 T1aN0M0 invasive adenocarcinoma patients, and re-classified achieved
surgical specimens according to the new International Association for the Study of Lung Cancer, American Thoracic
Society, and European Respiratory Society (IASLC/ATS/ERS) lung adenocarcinoma classification. Impact on
recurrence-free survival (RFS) for age, gender, smoking history, lymphovascular invasion (LVI) and new classification
was analyzed by log-rank test and Cox regression. Two existing prognostic grouping schemes of new classification
were compared, and subsequently, the correlation of high-grade group in the better prognostic grouping model
with clinical data was investigated statistically.
Results: The 5-year recurrence-free rate was 83.7%. The LVI and new adenocarcinoma classification were significantly
associated with 5-year RFS (P = 0.012; P = 0.022, respectively). The designation of papillary predominant subtype in the
low-grade group, along with lepidic- and acinar predominant subtype had more prognostic significance than the
model of combining papillary-, solid- and micropapillary predominant subtypes as the high-grade group (P = 0.005
versus P = 0.181). This high-grade group has increased risk of recurrence in a multivariate Cox regression (adjusted HR
2.815, 95% CI: 1.239 to 6.397, P = 0.013), and is associated significantly more with male gender (adjusted OR 2.214, 95%
CI: 1.050 to 4.668, P = 0.037), and, with borderline significance, the presence of LVI (adjusted OR 2.091, 95% CI: 0.938 to
4.662, P = 0.071).
Conclusions: Our results showed that the solid- and micropapillary predominant subtype of IASLC/ATS/ERS classification
remains the only risk factor for post-operative recurrence of T1aN0M0 adenocarcinomas, suggesting that they can be
indicators of aggressive tumor behaviors.
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predominant adenocarcinomaBackground
Lung carcinoma is one of leading causes of cancer death
worldwide, and its incidence rate continues to increase
[1]. Adenocarcinoma is the most common histologic type
of lung cancer, especially among Chinese women [2]. The
widespread use of computed tomography (CT) screening
encouraged by positive results of the National Lung* Correspondence: jwangmd@yahoo.com
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unless otherwise stated.Screening Trial is detecting more and more early-staged
adenocarcinomas [3,4]. T1aN0M0 constitutes the earliest
stage of invasive lung cancer. As the standard of care,
follow-up and surveillance without adjuvant therapy are
recommended after complete resection [5]. However,
some patients experience recurrence and die of lung can-
cer. According to the seventh lung cancer staging project
by the International Association for the Study of Lung
Cancer (IASLC), T1a non-small cell lung cancer (NSCLC)
has a 5-year survival of about 80% [6]. Therefore, thered. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mors for more careful follow-up and/or adjuvant therapy.
Many efforts have investigated the use of clinical,
radiologic, and histologic factors to refine the prognosis
of adenocarcinomas after surgical resection. Studies have
reported prognostic significance of gender [7,8], smoking
history [9], tumor size [10], degree of differentiation
[11], visceral pleural invasion [12], lymphovascular inva-
sion (LVI) [13,14], ground-glass opacity/solid ratio [15],
size of invasive tumor [16], maximum uptake on posi-
tron emission tomography (PET) scan [10,15]. Given the
fact that prognostic factors of lung cancer may vary with
tumor size [17], whether these factors have prognostic
value in T1aN0M0 adenocarcinomas is still unknown.
Remarkable advances in understanding lung adenocar-
cinoma have led to a new classification system, sponsored
by the IASLC, the American Thoracic Society (ATS), and
the European Respiratory Society (ERS) [18]. Several inde-
pendent studies have validated the prognostic significance
of new adenocarcinoma histologic subtypes [16,19,20], but
little attention has been paid to T1a tumors after radical
resection. However, previous studies of adenocarcinoma ≤
2 cm failed to include new classification into the analysis
[13,21,22]. The prognostic factors for completely resected
T1aN0M0 adenocarcinomas are still an open question. It
has been suggested that prognostic factors for lung cancer
may vary with tumor size [17].
The main purpose of our study was to determine the risk
factors for recurrence in a cohort of Chinese patients with
radically resected invasive T1aN0M0 adenocarcinoma.
Methods
Patients
This study was approved by the Institutional Review Board
of Peking University People’s Hospital. Consent from pa-
tients was waived as this study is retrospective and no
personal identifiable information was included in the
manuscript. We performed a retrospective review of a
prospectively maintained lung cancer database of all surgi-
cally resected NSCLC patients at our institution from
January 2004 to September 2011. The inclusion criteria in-
cluded complete resection by lobectomy with mediastinal
lymph node dissection and a definitive pathologic con-
firmation of T1aN0M0 lung adenocarcinoma. Those pa-
tients with preinvasive or minimally invasive lesions
defined by the new classification [18], or concurrent ma-
lignancy, or multiple tumors were excluded. Follow-up
was performed on an outpatient basis at three-month in-
tervals for the first two years and at six-month intervals
thereafter. In all, 177 patients were included in this study.
Parameters and histologic subtyping
Data extracted from each patient’s medical record in-
cluded age, sex, smoking history, tumor size and tumorgrading. Maximum uptake on PET scan was not chosen,
because it is size-dependent and there is controversy re-
garding the value of PET scanning for peripheral clinical
T1a lesions [23]. Measurements for percentage of ground-
glass opacity (GGO), which are proposed as an indicator
for less invasive tumor [15], were not included in the
present analysis.
All formalin-fixed surgical specimens were categorized
according to the IASLC/ATS/ERS classification of lung
adenocarcinoma [18]. Two pathologists reviewed all H&E-
stained slides, recording the percentage of each histologic
component in 5% increments, and discussing until con-
sensus was achieved. The predominant subtype was de-
fined as the pattern found with the largest proportion
[18]. The presence of lymphovascular invasion (LVI) was
defined as the presence of aggregates of tumor cells inside
vascular or lymphatic micro-vessels.
Endpoint
In the current study, recurrence-free survival (RFS) was
defined as time interval from surgery to the time of diag-
nosis of first definite clinical or pathologic evidence of
local recurrence or metastatic disease, lung cancer-
related death, or last follow-up. Patients were censored
if they were alive with recurrence-free status at the time
of the most recent follow-up or had died without docu-
mented recurrence. Overall survival was not an endpoint
for this study. The interest comes from the success of
epidermal growth factor receptor (EGFR) inhibitors,
which improve the median survival of late-staged EGFR
mutation-positive patients from about ten months with
chemotherapy alone [24], to over thirty months [25]. Prog-
nostic analysis of overall survival will be biased by predict-
ive factors, such as EGFR mutation, which associates with
female sex and the status of having never smoked [26].
Statistical analysis
The RFS was plotted by the Kaplan-Meier method, and
differences in RFS were assessed using the log-rank test.
Risk factors associated with RFS in univariate analysis
with Cox proportional hazards model analysis with a P-
value less than 0.10 were entered into a multivariate ana-
lysis. Correlation analysis of clinicopathologic variables
with histologic subtype groups was performed by Logistic
regression. A P-value less than 0.05 was considered statis-
tically significant. Statistical calculations were performed
using SPSS (version 16.0; SPSS, Chicago, IL, USA).
Results
Patient characteristic
Of the one hundred and ninety-eight patients who ful-
filled the inclusion criteria, eight patients were excluded
due to preinvasive adenocarcinoma, eight patients due
to multiple tumors and five patients due to concurrent
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tients were included in this study. The clinicopathologic
features including age, gender, smoking history, tumor
size, LVI and new IASLC/ATS/ERS classification are
listed in Table 1. More patients were female (98 patients,
55.4%) and the median age was 65 years (range 82 to
33 years). The median follow-up period was 44 months
(range 7 to 89 months).
All specimens were confirmed as invasive adenocarcin-
omas and then re-classified according to the criteria of the
IASLC/ATS/ERS classification of lung adenocarcinoma
[18]. The most frequent histologic subtype in our cohort
was acinar predominant, consisting of 58 cases (32.8%)
followed by lepidic predominant, comprising 45 tumors
(25.4%). Papillary-, micropapillary-, and solid predominant
adenocarcinomas accounted for 37 (20.9%), 19 (10.7%),
and 18 (10.2%) specimens respectively (Table 1). Variant
adenocarcinomas were not found.Table 1 Clinicopathologic characteristics of 177 patients
with invasive T1aN0M0 adenocarcinoma





≤ 65 97 83.7% 0.520
> 65 80 83.5%
Sex
Male 79 84.1% 0.855
Female 98 83.4%
Smoking history
Never-smoked 128 81.7% 0.424
Smoker 49 88.7%
Tumor size
≤ 1 cm 21 95.2% 0.231
> 1 to≤ 2 cm 156 82.2%
LVI
Absent 135 87.5% 0.012
Present 42 72.1%
Histological grading
Well differentiated 78 85.4% 0.535
Moderately differentiated 66 82.0%
Poorly differentiated 33 83.0%
Predominant subtypes





Abbreviations: LVI lymphovascular invasion, RFS recurrence-free survival.Survival analysis
During the median follow-up period, 24 recurrences were
documented, including 2 local recurrences and 22 distant
metastases (with/without local recurrence). Of these re-
currences, ten were confirmed pathologically, mostly by
fine-needle aspiration or supraclavicular lymph node bi-
opsy, and the remainder was defined by radiologic evi-
dence. Five-year RFS was 83.7% (Figure 1). Log-rank tests
of each parameter showed that the presence of LVI was a
significant predictor of 5-year RFS (72.1% versus 87.5%,
P = 0.012). Adenocarcinoma classification was also signifi-
cantly associated with risk of recurrence (P = 0.022). Le-
pidic predominant subtype had the highest 5-year RFS
(94.9%), followed by papillary predominant (91.9%). The
micropapillary predominant subtype had the lowest RFS
(57.6%), followed by the solid predominant (67.4%). The
acinar predominant subtype had a 5-year RFS of 83.1%
(Table 1).
In order to increase statistical power, we combined
predominant subtypes with similar survival into groups,
as was done in previous studies [16,19,27-29]. However, the
grouping schemes differ on the designation of papillary pre-
dominant tumors; whether it should be grouped as high-
grade [7,27,29] or intermediate-grade [16,19,28,30,31]. We
compared both grouping schemes on our cohort. For
model 1, the low-grade group included lepidic-, acinar-,
and papillary predominant adenocarcinomas, while the
high-grade group consisted of solid- and micropapillary
predominant tumors. Regarding model 2, the papillary pre-
dominant was designated also as the high-grade group.
Log-rank tests of both models showed designation of the
papillary predominant into the low-grade group better
stratified prognosis with respect to 5-year RFS (P = 0.005
for model 1 versus P = 0.181 for model 2) (Figure 2). Model
1 of grouping was used for further analysis in this study.
We then performed Cox multivariate survival analyses.
We included those factors that were significant in uni-
variate survival analysis, namely, sex, LVI, and pattern
groups. The analysis showed that the adenocarcinoma
subtype grouping (model 1) remained significantly asso-
ciated with RFS, with patients in the high-grade group
having an increased risk of recurrence, compared with
the low-grade group (adjusted hazard ratio (HR) 2.815,
95% CI: 1.239 to 6.397, P = 0.013) (Table 2). LVI only
showed borderline significance (adjusted HR 2.100, 95%
CI: 0.930 to 4.741, P = 0.074).
Correlation of more aggressive subtypes with
clinicopathologic variables
Finally, we performed correlation analysis to explore the
relationship between the clinicopathologic parameters and
the adenocarcinoma prognostic grouping by logistic re-
gression. Multivariate regression of significant variables in
univariate analysis showed significant association of male
Figure 1 Recurrence-free survival (RFS) of all 177 patients with invasive T1aN0M0 lung adenocarcinoma.
Figure 2 Probability of recurrence-free survival of different histologic prognostic groups. (A) In grouping scheme 1, the papillary
predominant subtype was designated in the low-grade group, along with lepidic- and acinar predominant subtypes. The low-grade group had significantly
lower probability of recurrence (P= 0.005). (B) Grouping scheme 2 combined papillary-, solid- and micropapillary predominant subtypes as the high-grade
group. The difference of probability of RFS between the low- and the high-grade groups failed to reach statistical significance (P= 0.181).
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Table 2 Multivariate analysis for five-year recurrence-free
survival (RFS)






Tumor size 0.079 2.974 (0.798 to 11.078) 0.104
LVI 0.016 2.100 (0.930 to 4.741) 0.074
Histological grading 0.362
Subtype grouping 0.008 2.815 (1.239 to 6.397) 0.013
Abbreviations: CI confidence interval, HR hazard ratio, LVI lymphovascular invasion.
Table 3 Correlation between clinicopathologic factors







Sex 0.036 2.214 (1.050 to 4.668) 0.037
Smoking history 0.469
Tumor size 0.884
LVI 0.070 2.091 (0.938 to 4.662) 0.071
Histological grading 0.225
Abbreviations: CI confidence interval, LVI lymphovascular invasion, OR odds ratio.
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95% CI: 1.050 to 4.668, P = 0.037). The statistical signifi-
cance for LVI was borderline (adjusted OR 2.091, 95% CI:
0.938 to 4.662, P = 0.071).
Discussion
To the best of our knowledge, the current study is the
first clinicopathologic prognostic analysis of T1aN0M0,
incorporating clinicopathologic and new IASLC/ATS/
ERS classification variables [13,22]. The only published
study investigating the prognostic utility of the classifica-
tion for patients with ≤ 2 cm adenocarcinomas focused on
the association of the percentage of micropapillary com-
ponent with recurrence, and between lobectomy versus
limited resection. We carefully designed this retrospective
study, trying to identify risk factors that can reflect accur-
ately the behaviors of early-staged lung adenocarcinomas.
Because adenocarcinoma in situ (AIS), and minimally
invasive adenocarcinoma (MIA) have 100% or near
100% disease specific survival after complete resection
[18], they were excluded in our study of risk factors for
recurrence. Visceral pleural invasion (VPI) was also ex-
cluded since it is not only determined by aggressiveness
of tumor, but also by its anatomic location. Although
one study which focused on adenocarcinomas < 2 cm
found no impact of VPI on recurrence or survival [32], a
nation-wide registry study confirmed the association of
worse survival with VPI in NSCLC of all sizes [33], and
the adverse impact of VPI was hypothesized as dissemin-
ation through parietal sub-pleural lymphatic drainage [34].
Moreover, we chose patients after radical lobectomy and
lymph node dissection, so that surgical margin-related re-
currence would not influence the analysis [35].
Our cohort of T1aN0M0 lung adenocarcinoma patients
had a 5-year RFS of 83.7%, similar to previous reports
[22,36]. The distribution of IASLC/ATS/ERS subtypes var-
ies considerably in the literature, which may have resulted
from differences between geographical regions and ethnic
populations (east versus west) [16,31], patient groups (all
stages versus stage I) [29], and the expertise of thepathologists [37]. The frequency of lepidic predominant
ranged from 26.7% reported by a Japanese study to 5.6%
in a US cohort, while that for papillary predominant
ranged from 40.9% to 4.7%. The percentage of micropapil-
lary ranged from 15.2% to 0 out of 191 adenocarcinomas
in a Japanese study. In the current study, the most fre-
quent histologic subtype was acinar predominant, com-
prising 58 out of 177 cases (32.8%), followed by lepidic
predominant, 25.4%. Papillary-, micropapillary-, and solid
predominant adenocarcinomas accounted for 37 (20.9%),
19 (10.7%), and 18 (10.2%) specimens respectively.
In common with previous reports [7,13,16,19,28-31,38,39],
our data confirmed the prognostic value of the IASLC/
ATS/ERS histologic classification, along with LVI, by log-
rank test. The 5-year RFS of lepidic predominant was
94.9%; papillary predominant, 91.9%; acinar predominant,
83.1%; solid predominant, 67.4%, and micropapillary pre-
dominant, 57.6%. To gain more statistical power, previous
studies combined subtype of similar prognosis to con-
struct a two-tiered or three-tiered grading scheme. How-
ever, difference remains regarding the designation of
papillary predominant adenocarcinomas. Interestingly,
most studies on Asian patients grouped this subtype into
lower- or intermediate-grade [16,19,28,30,31], while most
studies from western countries, grouped it into the high-
grade group [27,29] except that by Yoshizawa et al. [28].
Comparison of these two grouping schemes on our cohort
favored the former way of grouping (Figure 2, P = 0.005
versus P = 0.181), suggesting that the behaviors of papillary
predominant subtype may have ethnical differences. This
hypothesis can be supported by the findings in Asian pa-
tients of the association between EGFR mutation and pap-
illary predominant adenocarcinomas [39,40], but not in an
Australian cohort [27].
The observation that new histologic subtype grouping
remained the only risk factor for recurrence in patients
of T1aN0M0 disease on multivariate Cox regression,
and reported correlation of clinicopathologic variables
with histologic subtypes, promoted us to investigate the
relationship of these variables with subtype groupings.
We chose low-grade or high-grade as binary dependent
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son that the present study focused on recurrence risks,
which are more significantly related to subtype group-
ings. The correlation analysis confirmed the association
of male gender and presence of LVI (borderline signifi-
cant) with high-grade group (Table 3). Other researchers
have reported similar associations. Hung et al. found
that the lepidic predominant subtype is associated with
less smoking exposure, smaller tumor size, absence of
LVI, and well/moderately differentiated histologic grade,
while the high-grade group member, solid predominant, is
associated with male gender, smoking exposure, larger
tumor size, and poorly differentiated histologic grade [19].
Yanagawa and colleagues reported higher frequency of
smokers in solid predominant than in other subtypes [16].
Our results, along with these observations, suggested that
these clinicopathologic variables, such as gender, smoking
history and LVI, might not be independent prognostic fac-
tors, which may challenge the independency of these prog-
nostic factors, such as female gender [7].
The local infiltration ability and metastatic potential of
solid- and micropapillary predominant subtypes in the
high-grade group, may explain the increased risk of re-
currence. A recently published comparison of small
(≤2 cm) adenocarcinoma patients who underwent sublo-
bar resection versus lobectomy found that tumors with ≥
5% micropapillary component had more locoregional
recurrences after limited resection, especially those with
small surgical margins, but not in cases who underwent
lobectomies [35]. The authors suggested a greater cap-
acity for local infiltration of micropapillary subtype.
Likewise, a study of adenocarcinomas with N2 metasta-
sis suggested greater metastatic potential of micropapil-
lary and solid predominant subtypes, even though they may
not be the predominant subtype [27]. In a study of adeno-
carcinoma of post-operative adenocarcinomas at all stages,
Russell reported the highest incidence of N2 metastases
and invasion of lymphovascular spaces and visceral pleura
for micropapillary predominant adenocarcinoma [20]. In-
direct evidence also comes from a subtyping analysis of
stages I to IV adenocarcinomas, which showed the highest
rate of nodal metastases was for micropapillary predomin-
ant subtype (76%), followed by solid predominant (51%),
whereas for lepidic, the rate was only 7% [29]. However,
with respect to prognosis, the predominant subtype was
the main determinant [27,29].
There is growing interest in considering sublobar resec-
tion for early-stage lung cancer. To date, limited evidence
only supports the use of sublobar resection for subsolid le-
sions, a radiologic feature of preinvaisve or less invasive
tumors [5,41]. Histologic subtypes of adenocarcinoma
according to IASLC/ATS/ERS classification also stratifies
invasiveness and may have potential implication for select-
ing limited resection histologically, as suggested byNitadori [35]. However, the accuracy of reporting adenocar-
cinoma subtypes on frozen section is still an open question.
We acknowledge several limitations of our retrospective
study, which has a relatively small cohort of patients with
sub-optimal follow-up periods. The fact that even indolent
ground-glass opacity lesions can develop local recurrence
more than five years after resection [42] implied the neces-
sity of very long follow-up for these very early-staged cases.
Moreover, not all recurrences were biopsy-confirmed,
which is more accurate than radiologic evidence.
Conclusions
Our results showed that the solid- and micropapillary pre-
dominant subtype of IASLC/ATS/ERS classification remains
the only risk factor for post-operative recurrence of
T1aN0M0 adenocarcinomas, suggesting that they can be in-
dicators of aggressive tumor behaviors. We agree with the
proposal by Warth et al. that a tumor grading system based
on the predominant pattern might assist clinical decision-
making for pulmonary adenocarcinoma management [29].
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